Pharvaris (PHVS) Price & Analysis

Compare

107 Followers

PHVS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.51 - $26.33

Previous CloseN/A

Volume14.65K

Average Volume (3M)138.07K

Market Cap

$1.48B

Enterprise Value$728.99M

Total Cash (Recent Filing)$280.73M

Total Debt (Recent Filing)$861.47K

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Nov 05, 2025

EPS Estimate

-0.78

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.96

Shares Outstanding64,055,640

10 Day Avg. Volume128,747

30 Day Avg. Volume138,072

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.49

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.37K

Enterprise Value/Ebitda-5.01

Forecast

1Y Price Target

$35.57

Price Target Upside54.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical ProgressTarget enrollment in the RAPIDe-3 study was reached earlier this year, indicating strong progress in the study.

Financial StabilityPHVS ended the quarter with cash and cash equivalents of €200M, further strengthened through a $201M offering, extending the runway into 1H27.

Bears Say

Competitive Market DynamicsRecently approved Ekterly will still likely have a ~1.5 year head start and benefit from being the first oral approved in the on-demand setting.

Market ExclusivityEkterly, recently approved as the first oral on-demand HAE therapy, will have at least 12 months of market exclusivity before PHVS can enter the market.

Pharvaris News

Pharvaris price target lowered to $52 from $55 at Citizens JMP

Citizens JMP lowered the firm’s price target on Pharvaris (PHVS) to $52 from $55 and keeps an Outperform...

26d ago

PHVS

Pharvaris Advances Clinical Pipeline with Strong Financials

Pharvaris N.V. ( ($PHVS) ) has released its Q2 earnings. Here is a breakdown of the information Pharvaris...

19d ago

PHVS

Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Pharvaris, retaining the price target of $28.00....

24d ago

PHVS

Pharvaris: Buy Rating Backed by Promising Trial Milestones and Strong Financial Position

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on PHVS stock, giving a Buy rating today. Debanjana...

26d ago

PHVS

Pharvaris Reports Q2 2025 Financials and Advances Phase 3 Studies

Pharvaris ( ($PHVS) ) has shared an announcement. On August 12, 2025, Pharvaris reported its financial results for...

27d ago

PHVS

Pharvaris Raises $201 Million in Successful Offering

Pharvaris ( ($PHVS) ) has provided an announcement. On July 22, 2025, Pharvaris N.V. entered into an underwriting...

2M ago

PHVS

Pharvaris 8.25M share Spot Secondary priced at $20.00

he deal size was increased to $175M in common stock and warrants from $150M. Morgan Stanley, Leerink, Cantor...

2M ago

PHVS

Pharvaris announces $150M ordinary shares offering

Pharvaris (PHVS) N.V. announced that it intends to offer and sell $150M of ordinary shares in an underwritten...

2M ago

PHVS

Pharvaris’s Accelerated Phase 3 Trial Timeline and Market Potential Boost Buy Rating

Pharvaris, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maxwell Skor from Morgan...

2M ago

PHVS

Pharvaris’s Promising Outlook: Accelerated Timeline and Market Potential for Deucrictibant in HAE Treatment

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Pharvaris, with a price...

2M ago

PHVS

Pharvaris Updates RAPIDe-3 Study Timeline for HAE Treatment

The latest update is out from Pharvaris ( ($PHVS) ). On July 10, 2025, Pharvaris announced an update...

2M ago

PHVS

Pharvaris to report topline Phase 3 results of deucrictibant in Q4

Pharvaris (PHVS) updated the guidance for the disclosure of topline data from the ongoing RAPIDe-3 pivotal Phase 3...

2M ago

PHVS

Pharvaris Announces Key Resolutions from Annual General Meeting

An update from Pharvaris ( ($PHVS) ) is now available. On June 27, 2025, Pharvaris N.V. held its...

2M ago

PHVS

Pharvaris initiated with a Buy at Guggenheim on HAE potential

As previously reported, Guggenheim initiated coverage of Pharvaris (PHVS) with a Buy rating and $32 price target telling...

3M ago

PHVS

PHVS FAQ

What was Pharvaris’s price range in the past 12 months?

Pharvaris lowest stock price was $11.51 and its highest was $26.33 in the past 12 months.

What is Pharvaris’s market cap?

Pharvaris’s market cap is $1.48B.

When is Pharvaris’s upcoming earnings report date?

Pharvaris’s upcoming earnings report date is Nov 05, 2025 which is in 58 days.

How were Pharvaris’s earnings last quarter?

Pharvaris released its earnings results on Aug 12, 2025. The company reported -$0.963 earnings per share for the quarter, missing the consensus estimate of -$0.889 by -$0.074.

Is Pharvaris overvalued?

According to Wall Street analysts Pharvaris’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharvaris pay dividends?

Pharvaris does not currently pay dividends.

What is Pharvaris’s EPS estimate?

Pharvaris’s EPS estimate is -0.78.

How many shares outstanding does Pharvaris have?

Pharvaris has 64,055,640 shares outstanding.

What happened to Pharvaris’s price movement after its last earnings report?

Pharvaris reported an EPS of -$0.963 in its last earnings report, missing expectations of -$0.889. Following the earnings report the stock price went up 1.612%.

Which hedge fund is a major shareholder of Pharvaris?

Currently, no hedge funds are holding shares in PHVS

Pharvaris Stock Smart Score

Outperform

Fundamentals

Return on Equity

-63.96%

Trailing 12-Months

Asset Growth

-34.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris (PHVS) Earnings & Revenues

Historic Earnings Reports

PHVS Stock 12 Month Forecast

Average Price Target

$35.57

▲(54.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","23":"$23","33":"$33","43":"$43","53":"$53"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,23,33,43,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,22.46153846153846,24.923076923076923,27.384615384615387,29.846153846153847,32.30769230769231,34.769230769230774,37.23076923076923,39.69230769230769,42.15384615384615,44.61538461538461,47.07692307692308,49.53846153846154,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,21.197692307692307,22.395384615384614,23.59307692307692,24.79076923076923,25.988461538461536,27.186153846153847,28.383846153846154,29.58153846153846,30.779230769230768,31.976923076923075,33.174615384615386,34.37230769230769,{"y":35.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,19.692307692307693,19.384615384615383,19.076923076923077,18.76923076923077,18.46153846153846,18.153846153846153,17.846153846153847,17.53846153846154,17.23076923076923,16.923076923076923,16.615384615384613,16.307692307692307,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >